Results 71 to 80 of about 12,817 (217)

Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver

Lipids in Health and Disease, 2019
Background The homeostasis of lipid droplets (LDs) plays a crucial role in maintaining the physical metabolic processes in cells, and is regulated by many LD-associated proteins, including perilipin 5 (Plin5) in liver.
Jin Zhang, Xing Gao, Yuan Yuan, Chao Sun, Yuanlin Zhao, Liming Xiao, Ying Yang, Yu Gu, Risheng Yang, Peizhen Hu, Lijun Zhang, Chao Wang, Jing Ye   +12 more
doaj   +1 more source

Co-localisation of NS5A, dsRNA and PKR.

, 2023
(A) Huh7.5 cells were electroporated with mJFH-1 WT and DI mutant C142A, C190A and E191A RNAs and seeded on to coverslips. At 72 hpe cells were stained with sheep anti-NS5A (red), mouse anti-dsRNA J2 (white), rabbit anti-PKR (green) and DAPI.
Shucheng Chen (1419898), Mark Harris (33805)   +1 more
core   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors [PDF]

Antimicrobial Agents and Chemotherapy, 2017
ABSTRACT Hepatitis C virus (HCV) strains belong to seven genotypes with numerous subtypes that respond differently to antiviral therapies. Genotype 1, and primarily subtype 1b, is the most prevalent genotype worldwide. The development of recombinant HCV infectious cell culture systems for different variants, permitted by the high
Pham, Long V., Ramirez Almeida, Santseharay, Carlsen, Thomas H R, Li, Yi-Ping, Gottwein, Judith M., Bukh, Jens   +5 more
openaire   +3 more sources

NS5A dimer interface mutations altered subcellular distribution of NS5A.

, 2018
(A) Diagram of HJ3-5 encoding YFP-fused NS5A with different mutations at the top, western blot of NS5A, NS3 and tubulin in the middle, and virus titers at the bottom.
Alyssa K. Nichols (5545664), MinKyung Yi (362029), Saravanabalaji Shanmugam (5545667), Dhanaranjani Saravanabalaji (5545670), Christoph Welsch (22852)   +4 more
core   +1 more source

Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.

PLoS Pathogens, 2008
Persistent infection with the hepatitis C virus (HCV) is a major risk factor for the development of liver cirrhosis and hepatocellular carcinoma. With an estimated about 3% of the world population infected with this virus, the lack of a prophylactic ...
Nicole Appel, Margarita Zayas, Sven Miller, Jacomine Krijnse-Locker, Torsten Schaller, Peter Friebe, Stephanie Kallis, Ulrike Engel, Ralf Bartenschlager   +8 more
doaj   +1 more source

Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

Viruses, 2014
Direct-acting antivirals (DAAs) have significantly improved the treatment of infection with the hepatitis C virus. A promising class of novel antiviral agents targets the HCV NS5A protein.
Moheshwarnath Issur, Matthias Götte
doaj   +1 more source

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +1 more source

Dysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Dysregulated lipid metabolism facilitates hepatocellular carcinoma (HCC) development, progression, immunosuppressive tumor microenvironment (TME) formation, and therapeutic resistance. Notably, the patterns of lipid metabolism vary significantly among different types of HCC driven by various etiologies.
Yi Yi, Xi Liu, Xi Zhang, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source